Here are the DEF 14A proxy statements from Insmed, Inc. (INSM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow INSM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INSM filings page.
Insmed Incorporated is asking shareholders to vote at its virtual 2026 annual meeting on three items: electing two Class II directors, an advisory vote on 2025 executive pay, and ratifying Ernst & Young as auditor for 2026.
The company reports 2025 revenue of $606.4 million, driven by ARIKAYCE and the U.S. launch of BRINSUPRI, including a 19% year-over-year increase in global ARIKAYCE revenue and a stock price gain of over 150% in 2025. Insmed highlights a largely independent, skills-diverse Board, strong governance practices, and a pay program that is heavily equity-based and performance-linked, with about 94% of the CEO’s 2025 target direct compensation and 86% of other NEOs’ pay classified as “at risk.”